2020
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research
Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, Chuich T, Nouri SN, Dreyfus I, Driggin E, Sethi S, Sehgal K, Chatterjee S, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Bertoletti L, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Tafur AJ, Francese DP, Batra J, Falanga A, Clerkin KJ, Uriel N, Kirtane A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Leon MB, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Group T. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis And Haemostasis 2020, 120: 1004-1024. PMID: 32473596, PMCID: PMC7516364, DOI: 10.1055/s-0040-1713152.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2COVID-19Respiratory syndrome coronavirus 2Subgroup of patientsCOVID-19 patientsFuture prospective studiesManagement of thrombosisSyndrome coronavirus 2Coronavirus disease 2019Mechanism of actionViral illnessThrombotic eventsRandomized trialsProspective studyAntithrombotic effectCoronavirus 2Antithrombotic agentsAntithrombotic drugsAntiviral effectDisease 2019Thrombotic diseaseAntithrombotic propertiesDosing approachWorldwide pandemic
2015
Characterizing the US FDA's approach to promoting transformative innovation
Downing NS, Krumholz HM, Ross JS, Shah ND. Characterizing the US FDA's approach to promoting transformative innovation. Nature Reviews Drug Discovery 2015, 14: 740-741. PMID: 26435528, DOI: 10.1038/nrd4734.Peer-Reviewed Original Research
2013
How Do We Know the Value of Our Research?
Krumholz HM. How Do We Know the Value of Our Research? Circulation Cardiovascular Quality And Outcomes 2013, 6: 371-372. PMID: 23838103, PMCID: PMC5459392, DOI: 10.1161/circoutcomes.113.000423.Peer-Reviewed Original Research
2007
Time to Treatment in Primary Percutaneous Coronary Intervention
Nallamothu BK, Bradley EH, Krumholz HM. Time to Treatment in Primary Percutaneous Coronary Intervention. New England Journal Of Medicine 2007, 357: 1631-1638. PMID: 17942875, DOI: 10.1056/nejmra065985.Peer-Reviewed Original Research
2002
β-Blocker Therapy in Heart Failure: Scientific Review
Foody JM, Farrell MH, Krumholz HM. β-Blocker Therapy in Heart Failure: Scientific Review. JAMA 2002, 287: 883-889. PMID: 11851582, DOI: 10.1001/jama.287.7.883.Peer-Reviewed Original ResearchConceptsHeart failure patientsHeart failureClinical trialsFailure patientsClinical outcomesClass IIDrug Administration indicationsBeta-blocker usePrimary end pointΒ-blocker therapyScientific rationaleTreatment of patientsCare of patientsEnglish-language articlesPotential physiologic roleBasic science studiesClass of agentsSystolic dysfunctionMortality benefitPlacebo treatmentDATA EXTRACTIONClinical guidelinesSTUDY SELECTIONCurrent recommendationsPatients
1999
β-blockers for mild to moderate heart failure
Krumholz H. β-blockers for mild to moderate heart failure. The Lancet 1999, 353: 2-3. PMID: 10023937, DOI: 10.1016/s0140-6736(98)00413-9.Peer-Reviewed Original Research
1991
Reperfusion arrhythmias after thrombolysis. Electrophysiologic tempest, or much ado about nothing.
Krumholz HM, Goldberger AL. Reperfusion arrhythmias after thrombolysis. Electrophysiologic tempest, or much ado about nothing. CHEST Journal 1991, 99: 135s-140s. PMID: 2009810, DOI: 10.1378/chest.99.4.135s.Peer-Reviewed Original ResearchConceptsThrombolytic therapyMyocardial infarctionAcute myocardial infarctionSignificant clinical interestReperfusion arrhythmiasSuccessful reperfusionMyocardial reperfusionIdioventricular rhythmClinical eventsVentricular tachyarrhythmiasNoninvasive markerAnimal studiesArrhythmiasConsistent markerReperfusionClinical interestInfarctionTherapyCurrent dataMarkersThrombolysisTachyarrhythmias